Rosetta Genomics Ltd (ROSG)

0.80
0.02 2.40
NASDAQ : Health Care
Prev Close 0.82
Open 0.82
Day Low/High 0.78 / 0.89
52 Wk Low/High 0.71 / 3.25
Volume 367.90K
Avg Volume 125.60K
Exchange NASDAQ
Shares Outstanding 20.87M
Market Cap 18.36M
EPS -1.10
P/E Ratio 1.01
Div & Yield N.A. (N.A)

Latest News

Rosetta Genomics To Host 2016 Second Quarter Financial Results And Business Update Conference Call On September 26, 2016

Rosetta Genomics To Host 2016 Second Quarter Financial Results And Business Update Conference Call On September 26, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended...

Rosetta Genomics To Present At Upcoming September Conferences

Rosetta Genomics To Present At Upcoming September Conferences

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A.

Data Validating The Utility Of RosettaGX Reveal™ With Liquid-based Cytology Samples Will Be Presented At The 86th Annual Meeting Of The American Thyroid Association

Data Validating The Utility Of RosettaGX Reveal™ With Liquid-based Cytology Samples Will Be Presented At The 86th Annual Meeting Of The American Thyroid Association

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company's...

RosettaGX Reveal™ Thyroid MiRNA Classifier Now Available To Be Utilized On ThinPrep® Samples

RosettaGX Reveal™ Thyroid MiRNA Classifier Now Available To Be Utilized On ThinPrep® Samples

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company's first-of-its-kind microRNA classifier for indeterminate thyroid...

Rosetta Genomics Selected By A Global Pharmaceutical Company To Supply FISH Testing Services For Clinical Study In Prostate Cancer

Rosetta Genomics Selected By A Global Pharmaceutical Company To Supply FISH Testing Services For Clinical Study In Prostate Cancer

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global...

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of OncoGxSelect™ From Admera Health

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of OncoGxSelect™ From Admera Health

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect™, a next generation sequencing (NGS)-based test that...

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement With Galaxy Health Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement With Galaxy Health Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Galaxy...

Rosetta Genomics Receives U.S. Patent Allowance For MicroRNA-based Ovarian Cancer Treatment

Rosetta Genomics Receives U.S. Patent Allowance For MicroRNA-based Ovarian Cancer Treatment

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces that the United States Patent and Trademark Office (USPTO) has issued a...

Rosetta Genomics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Rosetta Genomics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Cantor Fitzgerald's 2 nd Annual Healthcare...

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc.

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of...

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for...

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health...

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31,...

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the 12 months ended December 31, 2015.

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.

Rosetta Genomics Appoints Ana C. Ward As Executive Vice President, Legal And Corporate Development

Rosetta Genomics Appoints Ana C. Ward As Executive Vice President, Legal And Corporate Development

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Ana C.

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of Three New Product Offerings

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of Three New Product Offerings

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces the launch of three high-value molecular diagnostic offerings in order to...

Rosetta Genomics Receives Approval From New York State For First-of-its-kind Thyroid Cancer Diagnostic Assay

Rosetta Genomics Receives Approval From New York State For First-of-its-kind Thyroid Cancer Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces conditional approval status for RosettaGX Reveal™, its novel microRNA...

Rosetta Genomics To Present At Source Capital's 2016 Disruptive Growth & Healthcare Conference

Rosetta Genomics To Present At Source Capital's 2016 Disruptive Growth & Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Source Capital's 2016 Disruptive Growth &...

Rosetta Genomics Announces Agreement With America's Choice Provider Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Announces Agreement With America's Choice Provider Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into an agreement with America's Choice Provider Network...

Rosetta Genomics Granted U.S. Patent Allowance For Use Of Gene Expression Signature For Classification Of Kidney Tumors

Rosetta Genomics Granted U.S. Patent Allowance For Use Of Gene Expression Signature For Classification Of Kidney Tumors

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent...

CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.

Rosetta Genomics Grants Sublicenses To Mirna Therapeutics For MicroRNA-related Patents For The Development Of Oncology Therapeutics

Rosetta Genomics Grants Sublicenses To Mirna Therapeutics For MicroRNA-related Patents For The Development Of Oncology Therapeutics

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide...

Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating

Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating

Rosetta Genomics (ROSG) stock surged on Friday after Cantor Fitzgerald initiated coverage on the stock with a 'speculative buy' rating.

4 Biotech Stocks Under $10 Poised for Big Breakouts

4 Biotech Stocks Under $10 Poised for Big Breakouts

These biotech stocks are within range of triggering breakout trades. Here's how to trade them now.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.